InVivoMAb mouse IgG2c isotype control, anti-dengue virus

Asthma is a heterogeneous disease characterized by airway inflammation and hyperresponsiveness (AHR). Ozone, a common air pollutant, induces a neutrophilic phenotype of asthma that is resistant to corticosteroids. Osteopontin has been implicated in airway inflammation, but its role in ozone-induced pulmonary responses remains unclear. We hypothesized that osteopontin contributes to neutrophilic airway inflammation and AHR through dendritic cell (DC)-neutrophil interactions.

Tumor-associated macrophages (TAMs) are key drivers of immunosuppressive inflammation in the breast cancer microenvironment, promoting tumor progression and resistance to immune checkpoint blockade. Our previous work identified extracellular IFI16/IFI202 as tumor-derived damage-associated molecular patterns which activate pro-inflammatory signaling in TAMs via Toll-like receptor 2, thereby facilitating immune evasion. In this study, we investigated the therapeutic potential of a monoclonal antibody (mAb) targeting extracellular IFI202 to suppress tumor-promoting inflammation and to restore antitumor immunity.

Recent studies have highlighted the therapeutic potential of targeting tumor neoantigens in solid tumors; however, its efficacy in breast cancer remains unclear. Here, we evaluate the impact of tumor neoantigen-targeted strategies in a syngeneic mouse mammary carcinoma model. Mice previously exposed to 4T1 tumor cells (PETCs) or treated with tumor cell-derived lysates (TdLs) exhibited robust antitumor immunity, leading to reduced tumor growth and metastasis through tumor immune microenvironment remodeling. TdL administration in mice harboring orthotopic tumors significantly enhanced the efficacy of immune checkpoint blockade, suggesting its potential as an immunotherapeutic adjuvant. To further optimize neoantigen-based approaches, we developed a lipid nanoparticle (LNP)-based delivery system for neoantigen peptides, which effectively suppressed tumor progression and metastasis in vivo. Mechanistically, this strategy promoted antigen-specific T cell activation and reshaped the tumor immune landscape, enhancing immune-mediated tumor rejection. These findings underscore the therapeutic promise of personalized tumor neoantigen-targeted immunotherapy in breast cancer and support its further evaluation in clinical settings.

Laminin comprises α/β/γ subunits and performs tissue-specific functions that control cellular behavior. Laminin-α2 chains are highly expressed in neural components such as glial and Schwann cells and in muscles. Macrophages play important roles in tissue homeostasis and repair, and laminins affect macrophage dynamics. Integrin α7, a transmembrane receptor crucial for regulating cell-matrix interactions, has a high affinity for laminin-α2, but its function in macrophages remains unknown. Here, we find that loss of integrin α7 signaling induces a dendritic cell (DC)-like phenotype in THP-1-derived macrophages and in primary monocytes-derived macrophages induced by granulocyte macrophage colony-stimulating factor cultured on laminin-α2 chains. Functional blocking of integrin α7 induced dendritic processes of THP-1-derived macrophages. Gene expression analysis revealed DC markers and costimulatory molecules, and coculture experiments demonstrated that the DC-like cells could stimulate T cell proliferation. Functional inhibition of integrin α7 decreased PI3K-p85α levels and activated PI3K, thereby activating AKT. Monocyte-derived macrophages cultured on laminin α2 chains decreased integrin α7 expression, exhibited dendritic-like morphology, and increased expression of DC markers and costimulatory molecules. These findings suggest that, besides the established influence of cytokine milieu, DC differentiation is regulated by laminin α2/integrin α7-mediated cell adhesion. Integrin α7 has been a therapeutic target in tumors, and antibody-based integrin α7 neutralization can be clinically useful. The results of this study suggest implications for integrin α7 and laminin-α2 chains in DC immunotherapy.